Drug Discovery Stories: From Bench to Bedside presents a collection of cases on the development of highly successful pharmaceuticals. It delves into the realm of drug discovery, exploring the structural biology and biological functions of the sought-after targets. The book covers the identification of promising compounds, their transformation from hits to leads through meticulous optimization, and the elucidation of how key compounds interact with the target (in essence, providing invaluable insights for drug design). Additionally, it covers essential information such as the pivotal biological and PK data of lead compounds, any noteworthy clinical results, and a comprehensive overview of other candidate compounds. The field of drug discovery and development has experienced rapid evolution, with numerous new drugs receiving approval each year. While several books have been published on this subject, there is a pressing need for a new book series that accurately reflects the current advancements in drug discovery. This book aims to not only cater to the drug discovery community but also engage other communities involved in chemical biology, synthetic chemistry, and pharmacology.
1. Principles and Strategies of New Drug Discovery
2. Structural biology-oriented antiviral drug discovery
3. Challenges of Clinical Drug Development
4. Azvudine: A Broad-Spectrum Antiviral Agent
5. Olverembatinib, A Third-Generation BCR-ABL1 Tyrosine Kinase Inhibitor for Cancer Treatment
6. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer
7. DKY709: An oral IKZF2/4-selective molecular glue degrader
8. PF-07258669: A Potent and Selective MC4R Antagonist for the Potential Treatment of Appetite Loss
9. RP-6306: An Orally Bioavailable and Selective PKMYT1 Inhibitor for the treatment of solid tumors
10. TQ1062: A Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors
11. BMS-986176: A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor for the Treatment of Neuropathic Pain
12. Darolutamide: An antiandrogen medication for the treatment of non-metastatic castration-resistant prostate cancer
13. JNJ-1802: An oral first-in-class DENV (NS3-NS4B) inhibitor
14. Revumenib: An oral menin-MLL1/KMT2A inhibitor
15. Repotrectinib (TPX-0005): A Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10. Peng Zhan obtained his B.S. degree from Shandong University, China, in 2005. He then earned his M.S. and Ph.D. degrees in medicinal chemistry from Shandong University in 2008 and 2010. He subsequently joined Shandong University as a Lecturer (20102012). From 2012 to 2014, he worked as a postdoctoral fellow funded by Japan Society for the Promotion of Science. He is currently a full professor in the Department of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel anti-viral (HIV, HBV, influenza, coronavirus, etc.), anti-gout, and anti-cancer agents based on rational drug design and combinatorial chemistry approaches. He also co-edited six books published by People's Medical Publishing House and Springer Nature, respectively and granted 50 patents (30 of them licensed). He currently serves as advisory editorial board member of Journal of Medicinal Chemistry.
